Literature DB >> 26206262

BODIPY: A Highly Versatile Platform for the Design of Bimodal Imaging Probes.

Damien Lhenry1, Manuel Larrouy1, Claire Bernhard1, Victor Goncalves1, Olivier Raguin2, Peggy Provent2, Mathieu Moreau1, Bertrand Collin1,3, Alexandra Oudot3, Jean-Marc Vrigneaud3, François Brunotte3, Christine Goze4, Franck Denat5.   

Abstract

In molecular imaging, multimodal imaging agents can provide complementary information, for improving the accuracy of disease diagnosis or enhancing patient management. In particular, optical/nuclear imaging may find important preclinical and clinical applications. To simplify the preparation of dual-labeled imaging agents, we prepared versatile monomolecular multimodal imaging probe (MOMIP) platforms containing both a fluorescent dye (BODIPY) and a metal chelator (polyazamacrocycle). One of the MOMIP was conjugated to a cyclopeptide (i.e., octreotide) and radiolabeled with (111) In. In vitro and in vivo studies of the resulting bioconjugate were conducted, highlighting the potential of these BODIPY-based bimodal probes. This work also confirmed that the biovector and/or the bimodal probes must be chosen carefully, due to the impact of the MOMIP on the overall properties of the resulting imaging agent.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  BODIPY; imaging agents; macrocycles; molecular imaging; optical imaging; positron emission tomography

Year:  2015        PMID: 26206262     DOI: 10.1002/chem.201501676

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  7 in total

1.  Synthesis of BODIPY-Peptide Conjugates for Fluorescence Labeling of EGFR Overexpressing Cells.

Authors:  Ning Zhao; Tyrslai M Williams; Zehua Zhou; Frank R Fronczek; Martha Sibrian-Vazquez; Seetharama D Jois; M Graça H Vicente
Journal:  Bioconjug Chem       Date:  2017-04-28       Impact factor: 4.774

Review 2.  Nuclear and Optical Bimodal Imaging Probes Using Sequential Assembly: A Perspective.

Authors:  Shin Hye Ahn; Eszter Boros
Journal:  Cancer Biother Radiopharm       Date:  2018-07-13       Impact factor: 3.099

3.  Bioorthogonal Fluorophore Linked DFO-Technology Enabling Facile Chelator Quantification and Multimodal Imaging of Antibodies.

Authors:  Labros G Meimetis; Eszter Boros; Jonathan C Carlson; Chongzhao Ran; Peter Caravan; Ralph Weissleder
Journal:  Bioconjug Chem       Date:  2015-12-30       Impact factor: 4.774

4.  Development of a multi faceted platform containing a tetrazine, fluorophore and chelator: synthesis, characterization, radiolabeling, and immuno-SPECT imaging.

Authors:  Anthony W McDonagh; Brooke L McNeil; Julie Rousseau; Ryan J Roberts; Helen Merkens; Hua Yang; François Bénard; Caterina F Ramogida
Journal:  EJNMMI Radiopharm Chem       Date:  2022-06-06

5.  Functionalization of theranostic AGuIX® nanoparticles for PET/MRI/optical imaging.

Authors:  Vivek Thakare; Vu-Long Tran; Marco Natuzzi; Eloïse Thomas; Mathieu Moreau; Anthony Romieu; Bertrand Collin; Alan Courteau; Jean-Marc Vrigneaud; Cédric Louis; Stéphane Roux; Frédéric Boschetti; Olivier Tillement; François Lux; Franck Denat
Journal:  RSC Adv       Date:  2019-08-09       Impact factor: 4.036

6.  Circularly Polarized Luminescence from Helically Chiral N,N,O,O-Boron-Chelated Dipyrromethenes.

Authors:  Rua B Alnoman; Sandra Rihn; Daniel C O'Connor; Fiona A Black; Bernard Costello; Paul G Waddell; William Clegg; Robert D Peacock; Wouter Herrebout; Julian G Knight; Michael J Hall
Journal:  Chemistry       Date:  2015-11-30       Impact factor: 5.236

7.  Aza-BODIPY: A New Vector for Enhanced Theranostic Boron Neutron Capture Therapy Applications.

Authors:  Ghadir Kalot; Amélie Godard; Benoît Busser; Jacques Pliquett; Mans Broekgaarden; Vincent Motto-Ros; Karl David Wegner; Ute Resch-Genger; Ulli Köster; Franck Denat; Jean-Luc Coll; Ewen Bodio; Christine Goze; Lucie Sancey
Journal:  Cells       Date:  2020-08-25       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.